NanoString Technologies

Cancer Research

Study Entire Pathways or Multiple Pathways in a Single Reaction

Leading cancer researchers worldwide are leveraging NanoString’s digital profiling technology to explore the frontiers of cancer biology. As the importance of studying the role of signaling pathways in cancer biology grows, many researchers are finding that the nCounter Analysis System is an indispensable tool for accelerating their research. With the capability to generate digital results for up to 800 targets in a single reaction, the nCounter system enables precise analysis of entire pathways (or multiple pathways) faster and with less bench time.

Chemistry Designed for Pathway-based Cancer Research

Highly multiplexed - 800 targets per reaction
No amplification - tolerant of FFPE and no bias
Precision - digital counting means unparalleled reproducibility
Simple and fast - easier, faster data production

Detailed information

CNV & Karyotyping

PAM50-based Breast Cancer Test

Introducing NanoString University (NanoU) an On-Demand Resource Portal

NanoU features course offerings ranging from self-guided videos as well as instructor led live & interactive courses.

Create your profile today for full access to all training material.

CNV & Karyotyping nCounter CNV CodeSets provide superior accuracy and reproducibility for studies of all sizes. Achieve better results faster and with substantially less effort than with qPCR or arrays. Product Highlights Better, faster results with less effort than qPCR or arrays Accurately target regions of interest Lowest hands-on time of any platform on the market Profile up to 800 regions of the human genome in a single reaction Detailed information

PAM50-based Breast Cancer Test NanoString Technologies obtained the CE Mark for its PAM50-based gene expression test for breast cancer, clearing the company to sell its test in the European Union and other countries recognizing the CE Mark. NanoString’s test provides a subtype classification based on the fundamental biology of an individual’s breast tumor (referred to as intrinsic subtyping), as well as a prognostic score that predicts the probability of cancer recurrence over 10 years in post-menopausal women with hormone receptor-positive, early stage breast cancer (ESBC) who have been treated with hormonal therapy. Together with studies from the literature, this information has been shown to convey valuable information about a patient’s prognosis that can inform critical decisions about the patient’s course of therapy. Detailed information